Takeda Pharmaceutical
TAK
$15.93
Share price
-2.21%
Change (1 day)
14.69%
Change (1 year)
Categories
Takeda Pharmaceutical (TAK) - P/B ratio
P/B ratio as of September 2023 : 1.04
According to Takeda Pharmaceutical's latest financial reports the company has a price-to-book ratio of 1.04.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Takeda Pharmaceutical - P/B ratio (from 2008 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | 1.03 | 11.47% |
| 2021-12-31 | 0.9217 | -27.15% |
| 2020-12-31 | 1.27 | -8.56% |
| 2019-12-31 | 1.38 | -2.36% |
| 2018-12-31 | 1.42 | -39.4% |
| 2017-12-31 | 2.34 | 25.64% |
| 2016-12-31 | 1.86 | -15.57% |
| 2015-12-31 | 2.20 | 43.79% |
| 2014-12-31 | 1.53 | -1.26% |
| 2013-12-31 | 1.55 | 8.32% |
| 2012-12-31 | 1.43 | 5.58% |
| 2011-12-31 | 1.36 | -9.3% |
| 2010-12-31 | 1.50 | 4.62% |
| 2009-12-31 | 1.43 | -33.87% |
| 2008-12-31 | 2.16 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.49 | 429.57% | 🇺🇸 USA |
 Novartis NVS | 4.07 | 291.99% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.83 | 76.63% | 🇺🇸 USA |
 Amgen AMGN | 21.3 | 1,948.85% | 🇺🇸 USA |
 Sanofi SNY | 1.72 | 65.50% | 🇫🇷 France |
 Merck MRK | 5.77 | 456.66% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.02 | 384.16% | 🇬🇧 UK |
 Seagen
SGEN | 14.8 | 1,326.00% | 🇺🇸 USA |
 Dr. Reddy's RDY | 3.99 | 284.20% | 🇮🇳 India |